These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 6709118)
21. Severe hyperkalemia in two patients with diabetes after cosyntropin administration. Feuerstein BL; Lebowitz MR; Blumenthal SA; Weinstock RS J Diabetes Complications; 1992; 6(3):203-6. PubMed ID: 1472747 [TBL] [Abstract][Full Text] [Related]
22. Life-threatening, preventable hyperkalemia in a nursing home resident: case report and literature review. Dharmarajan TS; Nguyen T; Russell RO J Am Med Dir Assoc; 2005; 6(6):400-5. PubMed ID: 16286062 [TBL] [Abstract][Full Text] [Related]
23. Short-term indomethacin administration does not impair excretion of acute potassium load in humans. Van Buren M; Van Rijn HJ; Koomans HA Eur J Clin Invest; 1992 Dec; 22(12):821-6. PubMed ID: 1478254 [TBL] [Abstract][Full Text] [Related]
29. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]. Santoro A; Mandreoli M G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183 [TBL] [Abstract][Full Text] [Related]
30. Clinical quiz: Mysterious hyperkalemia and cardiac arrest in a newborn infant undergoing continuous veno-venous hemofiltration dialysis: acute hyperkalemia. Bar-Joseph G; Tarabia M; Halberthal M; Khatib I; Eisenstein I; Zelikovic I Pediatr Nephrol; 2008 Jul; 23(7):1053-7. PubMed ID: 18431603 [No Abstract] [Full Text] [Related]
31. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Buysse JM; Huang IZ; Pitt B Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183 [TBL] [Abstract][Full Text] [Related]
33. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy. Schaefer JA; Gales MA Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290 [TBL] [Abstract][Full Text] [Related]
34. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients. Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP; Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355 [TBL] [Abstract][Full Text] [Related]
35. [Review on internal medicine, 1984. Electrolyte disturbance. II-3. Hyperkalemia in hyporeninemic hypoaldosteronism]. Saruta T Nihon Naika Gakkai Zasshi; 1985 Jun; 74(6):708-12. PubMed ID: 3900256 [No Abstract] [Full Text] [Related]
36. Hyperkalemia due to selective hypoaldosteronism. Arora KK; Pfeifer MA; Wolter C; Melo J; Samols E South Med J; 1977 May; 70(5):634-6. PubMed ID: 193197 [TBL] [Abstract][Full Text] [Related]
37. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174 [TBL] [Abstract][Full Text] [Related]
38. Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension. Kee CS; Choi JW; Chang DK; Ahn YH; Kim HJ J Korean Med Sci; 1993 Dec; 8(6):464-70. PubMed ID: 8179835 [TBL] [Abstract][Full Text] [Related]
39. Renal acidosis and renal potassium handling in selective hypoaldosteronism. Perez GO; Oster JR; Vaamonde CA Am J Med; 1974 Nov; 57(5):809-16. PubMed ID: 4440702 [No Abstract] [Full Text] [Related]
40. Reversal of glucose-induced hyperkalemia by sodium restriction in "normaldosteronemic" diabetes mellitus. Radó JP Endokrinologie; 1981 Dec; 78(2-3):244-52. PubMed ID: 7037374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]